301230.SZ
PharmaResources (Shanghai) Co., Ltd
SZSE · M 科研服务 · CN
CNY 33.84
−5.26%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 691.2M | 688.4M | 544.5M | 489.7M | 478.9M |
| Cost of Revenue | 495.6M | 499.6M | 414.5M | 338.5M | 302.3M |
| Gross Profit | 195.6M | 188.7M | 129.9M | 151.2M | 176.6M |
| Operating Expenses | |||||
| R&D Expense | 39.2M | 37.1M | 47.3M | 37.3M | 32.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 98.8M | 97.4M | 75.3M | 60.7M | 72.0M |
| Selling & Marketing Expense | 13.1M | 13.6M | 13.9M | 12.9M | 8.1M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 162.1M | 156.3M | 139.2M | 111.6M | 107.1M |
| Cost and Expenses | 657.7M | 655.9M | 553.7M | 450.1M | 409.4M |
| Operating Income (EBIT) | 43.9M | 28.6M | 3.6M | 37.4M | 72.8M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 43.2M | 28.3M | 3.5M | 36.8M | 72.9M |
| Income Tax Expense | (2.9M) | (6.0M) | (13.5M) | (856.5K) | 5.7M |
| Bottom Line | |||||
| Net Income | 46.1M | 34.3M | 17.1M | 37.6M | 67.2M |
| Earnings from Cont. Ops | 46.1M | 34.3M | 17.1M | 37.6M | 67.2M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 46.1M | 34.3M | 17.1M | 37.6M | 67.2M |
| Per Share | |||||
| Basic EPS | CN¥0.33 | CN¥0.25 | CN¥0.12 | CN¥0.27 | CN¥0.79 |
| Diluted EPS | CN¥0.33 | CN¥0.24 | CN¥0.12 | CN¥0.27 | CN¥0.79 |
| Revenue Per Share | CN¥4.94 | CN¥5.02 | CN¥3.82 | CN¥3.51 | CN¥5.63 |
| Shares | |||||
| Basic Shares Outstanding | 139.9M | 137.2M | 142.4M | 139.3M | 85.0M |
| Diluted Shares Outstanding | 139.9M | 137.2M | 142.4M | 139.3M | 85.0M |
| Profitability Metrics | |||||
| EBITDA | — | 100.2M | 58.4M | 71.2M | 98.5M |
| D&A | — | 71.5M | 54.7M | 33.8M | 25.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026